biostudies-literatureUnknown16Lee VH<h4>Background</h4>Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and compared to the erlotinib cohort.<h4>Methods</h4>Patients who suffered from metastatic EGFR-mutated NSCLC previously responsive to first-generation TKI and chemotherapy received afatinib until progression, loss of clinical benefits or intolerable toxicity. Treatment response, survival and safety were evaluated and compared to the erlotinib cohort.<h4>Results</h4>Twenty-five and 28 patients received afatinib and erlotinib respectively. More patienBMC cancer147https://www.ebi.ac.uk/biostudies/studies/S-EPMC4765101biostudies-literatureEfficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.PMC4765101Leung DKLam KOLee VHKwong DLLam PMChoy TSLeung TWfalseEfficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.<h4>Background</h4>Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and compared to the erlotinib cohort.<h4>Methods</h4>Patients who suffered from metastatic EGFR-mutated NSCLC previously responsive to first-generation TKI and chemotherapy received afatinib until progression, loss of clinical benefits or intolerable toxicity. Treatment response, survival and safety were evaluated and compared to the erlotinib cohort.<h4>Results</h4>Twenty-five and 28 patients received afatinib and erlotinib respectively. More patien2016-01-01T00:00:00Z2016 Feb2025-04-04T08:10:51.912Z2019-03-27T02:09:45ZS-EPMC47651012691131010.1186/s12885-016-2201-9